Quanterix/$QTRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Quanterix
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Ticker
$QTRX
Sector
Primary listing
Employees
450
Headquarters
Website
Quanterix Metrics
BasicAdvanced
$222M
-
-$2.51
1.12
-
Price and volume
Market cap
$222M
Beta
1.12
52-week high
$8.77
52-week low
$4.05
Average daily volume
613K
Financial strength
Current ratio
2.839
Quick ratio
1.982
Long term debt to equity
9.915
Total debt to equity
12.592
Profitability
EBITDA (TTM)
-71.927
Gross margin (TTM)
46.77%
Net profit margin (TTM)
-77.14%
Operating margin (TTM)
-62.33%
Effective tax rate (TTM)
4.56%
Revenue per employee (TTM)
$310,000
Management effectiveness
Return on assets (TTM)
-13.11%
Return on equity (TTM)
-34.25%
Valuation
Price to revenue (TTM)
1.449
Price to book
0.75
Price to tangible book (TTM)
1.6
Price to free cash flow (TTM)
-2.52
Free cash flow yield (TTM)
-39.67%
Free cash flow per share (TTM)
-1.873
Growth
Revenue change (TTM)
1.07%
Earnings per share change (TTM)
150.23%
3-year revenue growth (CAGR)
9.59%
10-year revenue growth (CAGR)
27.56%
3-year earnings per share growth (CAGR)
-2.27%
10-year earnings per share growth (CAGR)
-13.88%
What the Analysts think about Quanterix
Analyst ratings (Buy, Hold, Sell) for Quanterix stock.
Quanterix Financial Performance
Revenues and expenses
Quanterix Earnings Performance
Company profitability
Quanterix News
AllArticlesVideos
Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide
Business Wire·2 weeks ago
Quanterix to Participate in Upcoming Investor Conferences
Business Wire·3 weeks ago
Quanterix To Report Fourth Quarter and Full Year 2025 Financial Results on March 2, 2026
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Quanterix stock?
Quanterix (QTRX) has a market cap of $222M as of March 16, 2026.
What is the P/E ratio for Quanterix stock?
The price to earnings (P/E) ratio for Quanterix (QTRX) stock is 0 as of March 16, 2026.
Does Quanterix stock pay dividends?
No, Quanterix (QTRX) stock does not pay dividends to its shareholders as of March 16, 2026.
When is the next Quanterix dividend payment date?
Quanterix (QTRX) stock does not pay dividends to its shareholders.
What is the beta indicator for Quanterix?
Quanterix (QTRX) has a beta rating of 1.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.